Niek Wijnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Niek Wijnen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hugo W. A. M. de Jong
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
5 shared publications - Maarten Leonard Johannes Smits
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
5 shared publications - Rutger C. G. Bruijnen
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
5 shared publications Maarten L. J. Smits
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
3 shared publicationsEvert-Jan P. A. Vonken
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications- Guus Martinus Bol
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Gastrointestinal Medical Oncology, University of California, San Francisco (UCSF), San Francisco, the United States
2 shared publications
Latest Publications
- Open Access
Radioembolization with Intra-Arterial Angiotensin II to Improve Tumor-Absorbed Dose (RADIANT): A Single-Arm Phase II Study Protocol
Purpose: The effectiveness of transarterial radioembolization (TARE) depends largely on the tumor-to-non-tumor ratio (TNR): the ratio of microsphere concentration between tumor and non-tumorous liver tissue. Angiotensin II (AT-II) may improve TNR by inducing vasoconstriction primarily in arteries supplying healthy liver parenchyma. Tumor-feeding arteries, lacking neurovascular innervation, are largely unresponsive to AT-II, potentially resulting in preferential blood flow redistribution toward tumor tissue. The RADIANT study aims to evaluate whether intra-arterial AT-II infusion prior to yttrium-90 (90Y) microsphere injection improves tumor selectivity during TARE in patients with primary or metastatic liver tumors. Materials and Methods: This single-center, single-arm phase II study will include 15 patients with primary or metastatic liver tumors (any histological subtype, diameter ≥ 2 cm) referred for 90Y glass radioembolization. Each patient serves as their own control: during work-up, technetium-99m macroaggregated albumin (99mTc-MAA) is administered without AT-II and TNR is measured on SPECT/CT. During the therapeutic procedure, AT-II is infused intra-arterially (10 µg/min over 100 s) immediately before 90Y microsphere injection, and TNR is measured on post-treatment 90Y PET/CT. The primary endpoint is the TNR improvement factor (TNR after 90Y + AT-II divided by TNR after 99mTc-MAA). Secondary endpoints include toxicity and technical success of AT-II administration. Discussion: The RADIANT study will provide prospective evidence on the effect of intra-arterial AT-II infusion on tumor selectivity during 90Y radioembolization.
Open AccessRadioembolization with Intra-Arterial Angiotensin II to Improve Tumor-Absorbed Dose (RADIANT): A Single-Arm Phase II Study Protocol
Purpose: The effectiveness of transarterial radioembolization (TARE) depends largely on the tumor-to-non-tumor ratio (TNR): the ratio of microsphere concentration between tumor and non-tumorous liver tissue. Angiotensin II (AT-II) may improve TNR by inducing vasoconstriction primarily in arteries supplying healthy liver parenchyma. Tumor-feeding arteries, lacking neurovascular innervation, are largely unresponsive to AT-II, potentially resulting in preferential blood flow redistribution toward tumor tissue. The RADIANT study aims to evaluate whether intra-arterial AT-II infusion prior to yttrium-90 (90Y) microsphere injection improves tumor selectivity during TARE in patients with primary or metastatic liver tumors. Materials and Methods: This single-center, single-arm phase II study will include 15 patients with primary or metastatic liver tumors (any histological subtype, diameter ≥ 2 cm) referred for 90Y glass radioembolization. Each patient serves as their own control: during work-up, technetium-99m macroaggregated albumin (99mTc-MAA) is administered without AT-II and TNR is measured on SPECT/CT. During the therapeutic procedure, AT-II is infused intra-arterially (10 µg/min over 100 s) immediately before 90Y microsphere injection, and TNR is measured on post-treatment 90Y PET/CT. The primary endpoint is the TNR improvement factor (TNR after 90Y + AT-II divided by TNR after 99mTc-MAA). Secondary endpoints include toxicity and technical success of AT-II administration. Discussion: The RADIANT study will provide prospective evidence on the effect of intra-arterial AT-II infusion on tumor selectivity during 90Y radioembolization.
- Open Access
- 17 September 2026
- Published by Springer Nature in CVIR Oncology
- Vol. 2 (1) , 28
Dual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle
Selective radioembolization of liver tumors requires multiple injection positions, necessitating delivery catheter repositioning. Conventional single-lumen microcatheters risk guidewire contamination when repositioned after microsphere injection, requiring catheter disposal after each injection. We describe a technique using a dual-lumen microcatheter, in which one lumen accommodates the guidewire throughout the procedure while microspheres are injected through the second lumen, physically separating the two to prevent guidewire contamination and enable sequential injections from multiple positions. This approach was successfully applied in two patients undergoing radioembolization with multiple injection positions. This proof-of-principle investigation suggests that the dual-lumen technique may prevent guidewire contamination and may reduce material waste and procedure time. However, these findings require confirmation in larger studies.
- 17 September 2026
- Published by Springer Nature in CVIR Oncology
- Vol. 2 (1) , 28
Open AccessDual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle
Selective radioembolization of liver tumors requires multiple injection positions, necessitating delivery catheter repositioning. Conventional single-lumen microcatheters risk guidewire contamination when repositioned after microsphere injection, requiring catheter disposal after each injection. We describe a technique using a dual-lumen microcatheter, in which one lumen accommodates the guidewire throughout the procedure while microspheres are injected through the second lumen, physically separating the two to prevent guidewire contamination and enable sequential injections from multiple positions. This approach was successfully applied in two patients undergoing radioembolization with multiple injection positions. This proof-of-principle investigation suggests that the dual-lumen technique may prevent guidewire contamination and may reduce material waste and procedure time. However, these findings require confirmation in larger studies.
- Open Access
Is There a Role for Hepatobiliary Scintigraphy in Thermal Ablation of Hepatocellular Carcinoma?
Purpose: Hepatobiliary scintigraphy (HBS) provides quantitative assessment of (future remnant) liver function, aiding clinical decision-making for surgical resection and radioembolization of hepatocellular carcinoma (HCC). However, its role for thermal ablation remains unexplored. This pilot study aimed to explore the potential role of HBS in guiding patient selection and risk stratification for thermal ablation. Methods: All HCC patients who underwent thermal ablation between January 2021 and August 2025 and had HBS performed prior to ablation were retrospectively reviewed. Ablated non-tumor liver volumes (i.e., volume of ablated healthy parenchyma) were quantified using 3D segmentation. Absolute ablated liver function (i.e., the proportion of total HBS-derived liver function ablated) was also assessed. Clinical outcomes included changes in clinical scores (e.g., Child–Pugh) and the occurrence of hepatic decompensation after ablation. Results: Nine patients (13 tumors) were included. Median global HBS-derived liver function was 3.2%/min/m2 (range 1.6–6.8%/min/m2). Three patients developed hepatic decompensation > 3 months after ablation, unlikely related to thermal ablation itself. The patient with the lowest baseline function (1.6%/min/m2) tolerated ablation without hepatic decompensation. Median ablated non-tumor liver volume was 14.4 cm3 (range 3.1–46.7 cm3), corresponding to a median of 0.9% (range 0.2–3.6%) of total liver volume ablated per lesion. Median absolute ablated function was 0.05%/min/m2 (range 0.02–0.21%/min/m2). Conclusions: Thermal ablation was feasible and well tolerated even in patients with severely impaired liver function. Routine pre-ablation HBS does not appear necessary for thermal ablation of HCC, as only a small percentage of total functional liver volume is ablated.
Open AccessIs There a Role for Hepatobiliary Scintigraphy in Thermal Ablation of Hepatocellular Carcinoma?
Purpose: Hepatobiliary scintigraphy (HBS) provides quantitative assessment of (future remnant) liver function, aiding clinical decision-making for surgical resection and radioembolization of hepatocellular carcinoma (HCC). However, its role for thermal ablation remains unexplored. This pilot study aimed to explore the potential role of HBS in guiding patient selection and risk stratification for thermal ablation. Methods: All HCC patients who underwent thermal ablation between January 2021 and August 2025 and had HBS performed prior to ablation were retrospectively reviewed. Ablated non-tumor liver volumes (i.e., volume of ablated healthy parenchyma) were quantified using 3D segmentation. Absolute ablated liver function (i.e., the proportion of total HBS-derived liver function ablated) was also assessed. Clinical outcomes included changes in clinical scores (e.g., Child–Pugh) and the occurrence of hepatic decompensation after ablation. Results: Nine patients (13 tumors) were included. Median global HBS-derived liver function was 3.2%/min/m2 (range 1.6–6.8%/min/m2). Three patients developed hepatic decompensation > 3 months after ablation, unlikely related to thermal ablation itself. The patient with the lowest baseline function (1.6%/min/m2) tolerated ablation without hepatic decompensation. Median ablated non-tumor liver volume was 14.4 cm3 (range 3.1–46.7 cm3), corresponding to a median of 0.9% (range 0.2–3.6%) of total liver volume ablated per lesion. Median absolute ablated function was 0.05%/min/m2 (range 0.02–0.21%/min/m2). Conclusions: Thermal ablation was feasible and well tolerated even in patients with severely impaired liver function. Routine pre-ablation HBS does not appear necessary for thermal ablation of HCC, as only a small percentage of total functional liver volume is ablated.
- Open Access
- 26 August 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (1) , 59-69
Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication
Purpose: A tumor diameter > 3 cm is considered a relative contraindication for thermal ablation due to a significant risk of post-ablation recurrence. However, current advanced ablation techniques might allow for successful ablation of larger tumors. This study aimed to evaluate the impact of tumor size on outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA). Methods: Patients treated with HepACAGA for hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) between January 2021 and June 2025 were analyzed. All ablations were performed with microwave ablation. Patients were stratified by tumor size: ≤ 2 cm, 2–3 cm, and 3–5 cm. Outcomes assessed included local tumor progression-free survival (LTPFS), local tumor progression (LTP) rate, and complications. Results: A total of 137 consecutive patients with 265 tumors (152 HCC and 113 CRLM) were included: 187 tumors ≤ 2 cm, 52 tumors 2–3 cm, and 26 tumors 3–5 cm. The 1-year LTPFS was most favorable for tumors ≤ 2 cm (96%; 95% CI: 93–99), followed by 2–3 cm (93%; 95% CI: 85–100), and 3–5 cm (90%; 95% CI: 78–100). No significant differences in LTPFS were found ( p = 0.580). Overall, LTP occurred in 5% of tumors. Secondary LTP rates were 3% for tumors ≤ 2 cm and 4% for both tumors 2–3 cm and 3–5 cm ( p = 0.966). Complication rates were 4% for tumors ≤ 2 cm, 6% for tumors 2–3 cm, and 13% for tumors 3–5 cm ( p = 0.236). Conclusion: HepACAGA proved to be effective and safe for treating patients with HCC and CRLM across a broad range of tumor sizes. These findings suggest that intermediate-sized tumors (3–5 cm) could be eligible for thermal ablation without compromising post-ablation recurrence. Graphical
- 26 August 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (1) , 59-69
Open AccessImpact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication
Purpose: A tumor diameter > 3 cm is considered a relative contraindication for thermal ablation due to a significant risk of post-ablation recurrence. However, current advanced ablation techniques might allow for successful ablation of larger tumors. This study aimed to evaluate the impact of tumor size on outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA). Methods: Patients treated with HepACAGA for hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) between January 2021 and June 2025 were analyzed. All ablations were performed with microwave ablation. Patients were stratified by tumor size: ≤ 2 cm, 2–3 cm, and 3–5 cm. Outcomes assessed included local tumor progression-free survival (LTPFS), local tumor progression (LTP) rate, and complications. Results: A total of 137 consecutive patients with 265 tumors (152 HCC and 113 CRLM) were included: 187 tumors ≤ 2 cm, 52 tumors 2–3 cm, and 26 tumors 3–5 cm. The 1-year LTPFS was most favorable for tumors ≤ 2 cm (96%; 95% CI: 93–99), followed by 2–3 cm (93%; 95% CI: 85–100), and 3–5 cm (90%; 95% CI: 78–100). No significant differences in LTPFS were found ( p = 0.580). Overall, LTP occurred in 5% of tumors. Secondary LTP rates were 3% for tumors ≤ 2 cm and 4% for both tumors 2–3 cm and 3–5 cm ( p = 0.966). Complication rates were 4% for tumors ≤ 2 cm, 6% for tumors 2–3 cm, and 13% for tumors 3–5 cm ( p = 0.236). Conclusion: HepACAGA proved to be effective and safe for treating patients with HCC and CRLM across a broad range of tumor sizes. These findings suggest that intermediate-sized tumors (3–5 cm) could be eligible for thermal ablation without compromising post-ablation recurrence. Graphical
- Open Access
The Added Benefits of Performing Liver Tumor Ablation in the Angiography Suite: A Pictorial Essay of Combining C-Arm CT Guidance with Hepatic Arteriography for Liver Tumor Ablation
The HepACAGA (Hepatic Arteriography and C-arm CT-Guided Ablation) technique, which integrates C-arm CT guidance with transcatheter C-arm CT hepatic arteriography (C-arm CTHA), significantly improves liver tumor ablation outcomes by enhancing tumor visualization, navigation, and the intraprocedural assessment of ablation margins. The two key advantages of using C-arm CT over conventional CT for image guidance are firstly that the entire procedure can be performed in the angiography suite, eliminating the need for patient transfer between the angiography suite (catheterization) and CT-room (ablation), and secondly, that integrated C-arm needle guidance software can greatly reduce the difficulty of needle placement. Beyond these advantages, the HepACAGA technique offers additional benefits across four domains: (1) the direct conversion of ablation to intra-arterial liver-directed therapies (e.g., radioembolization or chemoembolization) upon the intraprocedural detection of disease progression; (2) the direct combination of ablation with intra-arterial treatments or portal vein embolization in one session; (3) the enhanced ablation effect through heat sink effect reduction with adjunct bland embolization or balloon occlusion; and (4) the immediate hemorrhage control through direct embolization. This pictorial essay demonstrates the advantages of combining C-arm CT guidance with real-time C-arm CTHA in the percutaneous thermal ablation of liver tumors, with clinical cases illustrating each of the aforementioned four key domains.
Open AccessThe Added Benefits of Performing Liver Tumor Ablation in the Angiography Suite: A Pictorial Essay of Combining C-Arm CT Guidance with Hepatic Arteriography for Liver Tumor Ablation
The HepACAGA (Hepatic Arteriography and C-arm CT-Guided Ablation) technique, which integrates C-arm CT guidance with transcatheter C-arm CT hepatic arteriography (C-arm CTHA), significantly improves liver tumor ablation outcomes by enhancing tumor visualization, navigation, and the intraprocedural assessment of ablation margins. The two key advantages of using C-arm CT over conventional CT for image guidance are firstly that the entire procedure can be performed in the angiography suite, eliminating the need for patient transfer between the angiography suite (catheterization) and CT-room (ablation), and secondly, that integrated C-arm needle guidance software can greatly reduce the difficulty of needle placement. Beyond these advantages, the HepACAGA technique offers additional benefits across four domains: (1) the direct conversion of ablation to intra-arterial liver-directed therapies (e.g., radioembolization or chemoembolization) upon the intraprocedural detection of disease progression; (2) the direct combination of ablation with intra-arterial treatments or portal vein embolization in one session; (3) the enhanced ablation effect through heat sink effect reduction with adjunct bland embolization or balloon occlusion; and (4) the immediate hemorrhage control through direct embolization. This pictorial essay demonstrates the advantages of combining C-arm CT guidance with real-time C-arm CTHA in the percutaneous thermal ablation of liver tumors, with clinical cases illustrating each of the aforementioned four key domains.
- Open Access
- 28 April 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (6) , 836-845
Renal Arteriography and C-arm CT-Guided Ablation (RenACAGA) for Thermal Ablation of Challenging Renal Tumors
Purpose: We present a technique that combines Renal arteriography with C-arm CT-Guided Ablation (RenACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of renal tumors. Materials and Methods: The RenACAGA technique was used for thermal ablation of challenging renal tumors (intraparenchymal or US-occult lesions). All patients treated with RenACAGA between January 1, 2022, and July 1, 2024, were retrospectively evaluated. Procedures were performed in the angiography suite, with catheterization of the renal artery for selective contrast infusion. C-arm CT and guidance software were used for tumor visualization and ablation needle placement. Pre- and post-ablation C-arm CTs were fused to assess ablation margins. Technical success and local tumor recurrence (LTR) rate were evaluated. Complications were graded according to the Common terminology criteria for adverse events (CTCAE) version 5.0. Results: Seven patients with 10 tumors were treated using the RenACAGA technique. All tumors were successfully identified, punctured and ablated (technical success 100%). During a median follow-up period of 8 months (range 7–25 months), no signs of tumor recurrence at the ablation site were observed (LTR rate 0%). One CTCAE grade 3 periprocedural complication was observed (urinary leakage through the needle tract), along with two CTCAE grade 1 complications (genitofemoral neuralgia (n = 1), and asymptomatic partial splenic infarction (n = 1)). Conclusion: The RenACAGA technique was successfully used for renal tumor ablation. Further studies are warranted to establish the potential benefits of this technique in terms of superior tumor visualization, targeting, ablation margin assessment, and combination with embolization. Graphical
- 28 April 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (6) , 836-845
Open AccessRenal Arteriography and C-arm CT-Guided Ablation (RenACAGA) for Thermal Ablation of Challenging Renal Tumors
Purpose: We present a technique that combines Renal arteriography with C-arm CT-Guided Ablation (RenACAGA) to improve tumor visualization, navigation and margin confirmation for percutaneous ablation of renal tumors. Materials and Methods: The RenACAGA technique was used for thermal ablation of challenging renal tumors (intraparenchymal or US-occult lesions). All patients treated with RenACAGA between January 1, 2022, and July 1, 2024, were retrospectively evaluated. Procedures were performed in the angiography suite, with catheterization of the renal artery for selective contrast infusion. C-arm CT and guidance software were used for tumor visualization and ablation needle placement. Pre- and post-ablation C-arm CTs were fused to assess ablation margins. Technical success and local tumor recurrence (LTR) rate were evaluated. Complications were graded according to the Common terminology criteria for adverse events (CTCAE) version 5.0. Results: Seven patients with 10 tumors were treated using the RenACAGA technique. All tumors were successfully identified, punctured and ablated (technical success 100%). During a median follow-up period of 8 months (range 7–25 months), no signs of tumor recurrence at the ablation site were observed (LTR rate 0%). One CTCAE grade 3 periprocedural complication was observed (urinary leakage through the needle tract), along with two CTCAE grade 1 complications (genitofemoral neuralgia (n = 1), and asymptomatic partial splenic infarction (n = 1)). Conclusion: The RenACAGA technique was successfully used for renal tumor ablation. Further studies are warranted to establish the potential benefits of this technique in terms of superior tumor visualization, targeting, ablation margin assessment, and combination with embolization. Graphical
- Open Access
Ablation of Small Liver Metastases Presenting as Foci of Diffusion Restriction on MRI–Results from the Prospective Minimally Invasive Thermal Ablation (MITA) Study
Purpose: Liver metastases presenting as small hyperintense foci on diffusion-weighted imaging (DWI) pose a therapeutic challenge. Ablation is generally not possible since these lesions are often occult on ultrasound and CT. The purpose of this prospective study was to assess if small liver metastases (≤10 mm) detected on DWI can be successfully localized and ablated with the Hepatic Arteriography and C-Arm CT-Guided Ablation technique (HepACAGA). Materials and Methods: All consecutive patients with small liver metastases (≤10 mm), as measured on DWI, referred for ablation with HepACAGA between 1 January 2021, and 31 October 2023, were included. Re-ablations and ablations concomitant with another local treatment were excluded. The primary outcome was the technical success rate, defined as the intraprocedural detection and subsequent successful ablation of small liver metastases using HepACAGA. Secondary outcomes included the primary and secondary local tumor progression (LTP) rates and the complication rate. Results: A total of 15 patients (26 tumors) were included, with liver metastases from colorectal cancer (73%), neuro-endocrine tumors (15%), breast cancer (8%) and esophageal cancer (4%). All 26 tumors were successfully identified, punctured and ablated (a technical success rate of 100%). After a median follow-up of 9 months, primary and secondary LTP were 4% and 0%, respectively. No complications occurred. Conclusion: In this proof-of-concept study, the HepACAGA technique was successfully used to detect and ablate 100% of small liver metastases identified on DWI with a low recurrence rate and no complications. This technique enables the ablation of subcentimeter liver metastases detected on MRI.
Open AccessAblation of Small Liver Metastases Presenting as Foci of Diffusion Restriction on MRI–Results from the Prospective Minimally Invasive Thermal Ablation (MITA) Study
Purpose: Liver metastases presenting as small hyperintense foci on diffusion-weighted imaging (DWI) pose a therapeutic challenge. Ablation is generally not possible since these lesions are often occult on ultrasound and CT. The purpose of this prospective study was to assess if small liver metastases (≤10 mm) detected on DWI can be successfully localized and ablated with the Hepatic Arteriography and C-Arm CT-Guided Ablation technique (HepACAGA). Materials and Methods: All consecutive patients with small liver metastases (≤10 mm), as measured on DWI, referred for ablation with HepACAGA between 1 January 2021, and 31 October 2023, were included. Re-ablations and ablations concomitant with another local treatment were excluded. The primary outcome was the technical success rate, defined as the intraprocedural detection and subsequent successful ablation of small liver metastases using HepACAGA. Secondary outcomes included the primary and secondary local tumor progression (LTP) rates and the complication rate. Results: A total of 15 patients (26 tumors) were included, with liver metastases from colorectal cancer (73%), neuro-endocrine tumors (15%), breast cancer (8%) and esophageal cancer (4%). All 26 tumors were successfully identified, punctured and ablated (a technical success rate of 100%). After a median follow-up of 9 months, primary and secondary LTP were 4% and 0%, respectively. No complications occurred. Conclusion: In this proof-of-concept study, the HepACAGA technique was successfully used to detect and ablate 100% of small liver metastases identified on DWI with a low recurrence rate and no complications. This technique enables the ablation of subcentimeter liver metastases detected on MRI.
- Open Access
Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis
Purpose: Hepatic Arteriography and C-Arm CT-Guided Ablation of liver tumors (HepACAGA) is a novel technique, combining hepatic–arterial contrast injection with C-arm CT-guided navigation. This study compared the outcomes of the HepACAGA technique with patients treated with conventional ultrasound (US) and/or CT-guided ablation. Materials and Methods: In this retrospective cohort study, all consecutive patients with hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) treated with conventional US-/CT-guided ablation between 1 January 2015, and 31 December 2020, and patients treated with HepACAGA between 1 January 2021, and 31 October 2023, were included. The primary outcome was local tumor recurrence-free survival (LTRFS). Secondary outcomes included the local tumor recurrence (LTR) rate and complication rate. Results: 68 patients (120 tumors) were included in the HepACAGA cohort and 53 patients (78 tumors) were included in the conventional cohort. In both cohorts, HCC was the predominant tumor type (63% and 73%, respectively). In the HepACAGA cohort, all patients received microwave ablation. Radiofrequency ablation was the main ablation technique in the conventional group (78%). LTRFS was significantly longer for patients treated with the HepACAGA technique (p = 0.015). Both LTR and the complication rate were significantly lower in the HepACAGA cohort compared to the conventional cohort (LTR 5% vs. 26%, respectively; p < 0.001) (complication rate 4% vs. 15%, respectively; p = 0.041). Conclusions: In this study, the HepACAGA technique was safer and more effective than conventional ablation for HCC and CRLM, resulting in lower rates of local tumor recurrence, longer local tumor recurrence-free survival and fewer procedure-related complications.
Open AccessConventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis
Purpose: Hepatic Arteriography and C-Arm CT-Guided Ablation of liver tumors (HepACAGA) is a novel technique, combining hepatic–arterial contrast injection with C-arm CT-guided navigation. This study compared the outcomes of the HepACAGA technique with patients treated with conventional ultrasound (US) and/or CT-guided ablation. Materials and Methods: In this retrospective cohort study, all consecutive patients with hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) treated with conventional US-/CT-guided ablation between 1 January 2015, and 31 December 2020, and patients treated with HepACAGA between 1 January 2021, and 31 October 2023, were included. The primary outcome was local tumor recurrence-free survival (LTRFS). Secondary outcomes included the local tumor recurrence (LTR) rate and complication rate. Results: 68 patients (120 tumors) were included in the HepACAGA cohort and 53 patients (78 tumors) were included in the conventional cohort. In both cohorts, HCC was the predominant tumor type (63% and 73%, respectively). In the HepACAGA cohort, all patients received microwave ablation. Radiofrequency ablation was the main ablation technique in the conventional group (78%). LTRFS was significantly longer for patients treated with the HepACAGA technique (p = 0.015). Both LTR and the complication rate were significantly lower in the HepACAGA cohort compared to the conventional cohort (LTR 5% vs. 26%, respectively; p < 0.001) (complication rate 4% vs. 15%, respectively; p = 0.041). Conclusions: In this study, the HepACAGA technique was safer and more effective than conventional ablation for HCC and CRLM, resulting in lower rates of local tumor recurrence, longer local tumor recurrence-free survival and fewer procedure-related complications.